Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic.
about
Tumor necrosis factor-alpha induces Bax-Bak interaction and apoptosis, which is inhibited by adenovirus E1B 19KRegulation of the cell cycle and apoptosis by the oncogenes of adenovirusExpanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenovirusesIncreased sensitivity to staphylococcal enterotoxin B following adenoviral infectionTumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death proteinTissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy."Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lungInhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins.E1B 19K blocks Bax oligomerization and tumor necrosis factor alpha-mediated apoptosis.Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathwayGene delivery from replication-selective viruses: arming guided missiles in the war against cancer.The dynamics of E1A in regulating networks and canonical pathways in quiescent cellsNonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disordersAdenovirus infections in immunocompetent and immunocompromised patients.Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs.The promise and potential hazards of adenovirus gene therapy.The human adenovirus type 5 E1B 55 kDa protein obstructs inhibition of viral replication by type I interferon in normal human cells.E1A sensitizes cells to tumor necrosis factor alpha by downregulating c-FLIP S.Inhibition of chemokine expression by adenovirus early region three (E3) genes.Mutations within the ADP (E3-11.6K) protein alter processing and localization of ADP and the kinetics of cell lysis of adenovirus-infected cells.A systematic comparison of the anti-tumoural activity and toxicity of the three Adv-TKsInducible nitric oxide synthase expression inhibition by adenovirus E1A.Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunityFunctions and mechanisms of action of the adenovirus E3 proteins.Adenovirus type 5 exerts genome-wide control over cellular programs governing proliferation, quiescence, and survival.Oncolytic viral therapies.Adenovirus as an emerging pathogen in immunocompromised patients.Novel molecular approaches to cystic fibrosis gene therapy.Adenoviruses in fecal samples from asymptomatic rhesus macaques, United States.T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients.Adenovirus infection after allogeneic stem cell transplantation.Innate immunity to adenovirus.Improving adenovirus based gene transfer: strategies to accomplish immune evasion.Prospects for oral replicating adenovirus-vectored vaccines.Adenovirus-triggered innate signalling pathways.The use of β-cell transcription factors in engineering artificial β cells from non-pancreatic tissue.Characterization of Ad5 E3-14.7K, an adenoviral inhibitor of apoptosis: structure, oligomeric state, and metal binding.Profile of expression of certain markers of apoptosis in chronic hepatitis C and hepatitis B patients in an Egyptian population.Novel permissive murine immunocompetent orthotopic colon carcinoma model for comparison of the antitumoral and safety profiles of three Adv-TKs.
P2860
Q24291723-31C3CA0A-69E3-4081-B291-F30EC8A3B207Q29037634-765AF254-AAB4-46D2-B411-D6C646D4FBECQ33622711-C7A9E546-0176-4BF9-B4F9-2DF2B0C5BD11Q33755007-96F42883-CAF3-4A16-A67E-B47736F4461AQ33788137-33C4EF58-3791-4FD3-841E-5655D0755236Q33807026-42501C66-6128-48C1-9246-89D296E5FDCDQ33838380-BCCD2EE9-0B79-4267-ABC1-31869C744DFCQ33841039-EC4E459E-4FD4-4D08-80C4-98BD90F27B85Q33844897-CAA9ADC8-604F-4DBB-A727-991A7E62D34FQ33852843-7EB85B7C-9F95-4F06-92F4-FF75B192B0FEQ33865835-801C7F7E-12C3-423F-90AD-4DC6B51C4F86Q33904270-B25C93F8-112E-4DB3-938C-CEE6269B311BQ33912982-3CC78659-B726-4C2D-AD6E-300D0A0B8FD6Q33985663-A90CE5A4-35C0-4E64-A7FC-7ED148CB7222Q34057627-12B6C377-52D2-4E40-9DAA-A3B288A403A7Q34157554-24D61A06-5768-4DB9-98B1-0EE7C773F71AQ34219407-ECB33166-A3AB-45C6-86EA-DC04BF9387EFQ34388476-AD385DFB-7246-4167-806E-F6AC4431D57EQ34472155-F35F963A-382A-4AB9-AA96-963F57093EDFQ35000763-E8B3A088-3D03-4899-8D58-A6E9664F6A61Q35105144-0632899F-1353-4432-8467-CE1357DC85C6Q35145614-762B41C7-46D7-407A-B7A9-2B957B326315Q35146799-FB0DE2CE-C9C6-489F-B4E8-1DBB98DD7A0BQ35155049-1BF8FBDE-3BB9-412F-A154-75E06065FF94Q35613800-A62CD8D0-470E-4677-9151-5454721B5D8AQ35850341-69C03677-7146-4A1F-BEF5-DDA800BCBD29Q35852258-367E2569-9771-403C-ACF6-2119EB24C370Q36003090-42336F4A-C8D5-499C-A3A2-F56E7141AA51Q36012920-83871678-F5D3-4589-B895-FDB062556403Q36037740-2A6C34A3-06E0-4716-87B9-3A81ADFD29ADQ36388658-B931A02A-A267-43E1-B815-E6E062117C84Q36746433-FE15B98E-1B03-4231-B693-4430C32060DFQ37718852-C6DAF686-72A6-4B8F-A913-7F909F03B9F9Q37945219-F92C7DC9-F044-45D2-98AA-F09E424EB295Q38109356-B434F88D-DD39-474A-AE33-1A7F9A963040Q38187126-B3347DCF-5C5D-4C52-AD04-66D5AC9A8814Q38262028-78497450-F7EB-4286-ACAD-5C2C0A0DEAA1Q38269484-CFFA8AA0-F2B4-4188-9535-69B8369C5B3FQ38986522-B99752B2-9CA4-4792-A9E7-668352D73607Q39135464-AA559733-C869-471E-A6EB-F65D39336D94
P2860
Immune responses to adenoviruses: viral evasion mechanisms and their implications for the clinic.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Immune responses to adenovirus ...... r implications for the clinic.
@ast
Immune responses to adenovirus ...... r implications for the clinic.
@en
type
label
Immune responses to adenovirus ...... r implications for the clinic.
@ast
Immune responses to adenovirus ...... r implications for the clinic.
@en
prefLabel
Immune responses to adenovirus ...... r implications for the clinic.
@ast
Immune responses to adenovirus ...... r implications for the clinic.
@en
P2093
P1476
Immune responses to adenovirus ...... ir implications for the clinic
@en
P2093
Kuppuswamy M
Lichtenstein DL
Tollefson AE
P304
P356
10.1016/S0952-7915(99)80064-8
P50
P577
1999-08-01T00:00:00Z